{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:18:46Z","timestamp":1782307126950,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00520-022-07320-y","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T11:09:04Z","timestamp":1660648144000},"page":"9071-9078","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"30","author":[{"given":"Onur","family":"Bas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2487-2087","authenticated-orcid":false,"given":"Enes","family":"Erul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz Can","family":"Guven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"7320_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"7320_CR2","first-page":"216","volume":"32","author":"M Shah","year":"2018","unstructured":"Shah M, Nunes MR, Stearns V (2018) CDK4\/6 inhibitors: game changers in the management of hormone receptor\u2013positive advanced breast cancer? Oncology (Williston Park) 32(5):216\u2013222","journal-title":"Oncology (Williston Park)"},{"issue":"32","key":"7320_CR3","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tr\u00e9dan O, Chen SC, Manso L et al (2017) monarch 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35(32):3638\u20133646","journal-title":"J Clin Oncol"},{"issue":"4","key":"7320_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S et al (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17(4):425\u2013439","journal-title":"Lancet Oncol"},{"issue":"24","key":"7320_CR5","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Mart\u00edn M et al (2018) Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36(24):2465\u20132472","journal-title":"J Clin Oncol"},{"issue":"2","key":"7320_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discovery 14(2):130\u2013146","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"7320_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K et al (2015) Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373(3):209\u2013219","journal-title":"N Engl J Med"},{"issue":"1","key":"7320_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13058-016-0721-5","volume":"18","author":"RS Finn","year":"2016","unstructured":"Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, Pinter T, Boer K, Patel R, Randolph S et al (2016) Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1\/TRIO-18. Breast Cancer Res: BCR 18(1):67","journal-title":"Breast Cancer Res: BCR"},{"issue":"18","key":"7320_CR9","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andr\u00e9 F, Winer EP et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738\u20131748","journal-title":"N Engl J Med"},{"issue":"1","key":"7320_CR10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2019","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA et al (2019) The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 6(1):116\u2013124","journal-title":"JAMA Oncol"},{"issue":"25","key":"7320_CR11","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA et al (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35(25):2875\u20132884","journal-title":"J Clin Oncol"},{"issue":"6","key":"7320_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Mart\u00edn M et al (2020) Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 382(6):514\u2013524","journal-title":"N Engl J Med"},{"issue":"7","key":"7320_CR13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS et al (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19(7):904\u2013915","journal-title":"Lancet Oncol"},{"issue":"4","key":"7320_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"SA Im","year":"2019","unstructured":"Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S et al (2019) Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381(4):307\u2013316","journal-title":"N Engl J Med"},{"issue":"2","key":"7320_CR15","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/j.clbc.2019.08.009","volume":"20","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Finn RS, Gelmon K, Joy AA, Harbeck N, Castrellon A, Mukai H, Walshe JM, Mori A, Gauthier E et al (2020) Progression-free survival outcome is independent of objective response in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with palbociclib plus letrozole compared with letrozole: analysis from PALOMA-2. Clin Breast Cancer 20(2):e173\u2013e180","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"7320_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","volume":"174","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Finn RS, Di\u00e9ras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR et al (2019) Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 174(3):719\u2013729","journal-title":"Breast Cancer Res Treat"},{"key":"7320_CR17","doi-asserted-by":"publisher","first-page":"175883592096392","DOI":"10.1177\/1758835920963925","volume":"12","author":"QY Zhang","year":"2020","unstructured":"Zhang QY, Sun T, Yin YM, Li HP, Yan M, Tong ZS, Oppermann CP, Liu YP, Costa R, Li M et al (2020) MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2- advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol 12:1758835920963925","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"7320_CR18","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(20)30112-1","volume":"21","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A et al (2020) Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol 21(6):763\u2013775","journal-title":"Lancet Oncol"},{"issue":"3","key":"7320_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1200\/JCO.18.01624","volume":"37","author":"S Johnston","year":"2019","unstructured":"Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, Boileau JF, Provencher L, Robidoux A, Rimawi M et al (2019) Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. J Clin Oncol 37(3):178\u2013189","journal-title":"J Clin Oncol"},{"issue":"8","key":"7320_CR20","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1093\/annonc\/mdy214","volume":"29","author":"L Malorni","year":"2018","unstructured":"Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D\u2019Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C et al (2018) Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Ann Oncol 29(8):1748\u20131754","journal-title":"Ann Oncol"},{"key":"7320_CR21","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"7320_CR22","doi-asserted-by":"crossref","unstructured":"Piezzo M, Chiodini P, Riemma M, Cocco S, Caputo R, Cianniello D, Di Gioia G, Di Lauro V, Rella FD, Fusco G et al (2020) Progression-free survival and overall survival of CDK 4\/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis. Int J Mol Sci 21(17)","DOI":"10.3390\/ijms21176400"},{"issue":"2","key":"7320_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","volume":"21","author":"JJ Gao","year":"2020","unstructured":"Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, Amiri-Kordestani L, Ibrahim A, Sridhara R, Goldberg KB et al (2020) CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol 21(2):250\u2013260","journal-title":"Lancet Oncol"},{"issue":"5","key":"7320_CR24","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1016\/j.clbc.2018.04.017","volume":"18","author":"Y Deng","year":"2018","unstructured":"Deng Y, Ma G, Li W, Wang T, Zhao Y, Wu Q (2018) CDK4\/6 inhibitors in combination with hormone therapy for HR(+)\/HER2(-) advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Clin Breast Cancer 18(5):e943\u2013e953","journal-title":"Clin Breast Cancer"},{"issue":"20","key":"7320_CR25","doi-asserted-by":"publisher","first-page":"e10746","DOI":"10.1097\/MD.0000000000010746","volume":"97","author":"W Ding","year":"2018","unstructured":"Ding W, Li Z, Wang C, Ruan G, Chen L, Tu C (2018) The CDK4\/6 inhibitor in HR-positive advanced breast cancer: a systematic review and meta-analysis. Medicine 97(20):e10746","journal-title":"Medicine"},{"issue":"1","key":"7320_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10549-018-4901-0","volume":"172","author":"C Messina","year":"2018","unstructured":"Messina C, Cattrini C, Buzzatti G, Cerbone L, Zanardi E, Messina M, Boccardo F (2018) CDK4\/6 inhibitors in advanced hormone receptor-positive\/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat 172(1):9\u201321","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"7320_CR27","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1158\/1078-0432.CCR-15-1421","volume":"22","author":"W Hu","year":"2016","unstructured":"Hu W, Sung T, Jessen BA, Thibault S, Finkelstein MB, Khan NK, Sacaan AI (2016) Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies. Clin Cancer Res 22(8):2000\u20132008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7320_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13027-021-00413-z","volume":"16","author":"M Elhadi","year":"2021","unstructured":"Elhadi M, Khaled A, Msherghi A (2021) Infectious diseases as a cause of death among cancer patients: a trend analysis and population-based study of outcome in the United States based on the surveillance, epidemiology, and end results database. Infect Agents Cancer 16(1):72","journal-title":"Infect Agents Cancer"},{"issue":"3","key":"7320_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11912-019-0769-3","volume":"21","author":"LM Spring","year":"2019","unstructured":"Spring LM, Wander SA, Zangardi M, Bardia A (2019) CDK 4\/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep 21(3):25","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"7320_CR30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10549-021-06215-6","volume":"188","author":"KB Kristensen","year":"2021","unstructured":"Kristensen KB, Thomsen IMN, Berg T, Kodahl AR, Jensen AB (2021) Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer. Breast Cancer Res Treat 188(3):799\u2013809","journal-title":"Breast Cancer Res Treat"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07320-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07320-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07320-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T10:37:40Z","timestamp":1667471860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07320-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["7320"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07320-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"assertion":[{"value":"19 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}